Literature DB >> 28295502

Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept.

Marina Ramirez-Alvarado1,2, David R Barnidge3, David L Murray3, Angela Dispenzieri4, Marta Marin-Argany1, Christopher J Dick1, Shawna A Cooper1, Samih H Nasr3, Christopher J Ward5, Surendra Dasari6, Víctor H Jiménez-Zepeda7, Nelson Leung4,8.   

Abstract

Immunoglobulin light chain (AL) amyloidosis is a fatal complication of B-cell proliferation secondary to deposition of amyloid fibrils in various organs. Urinary exosomes (UEX) are the smallest of the microvesicles excreted in the urine. Previously, we found UEX of patients with AL amyloidosis contained immunoglobulin light chain (LC) oligomers that patients with multiple myeloma did not have. To further explore the role of the LC oligomers, UEX was isolated from an AL amyloidosis patient with progressive renal disease despite achieving a complete response. LC oligomers were identified. Mass spectrometry (MS) of the UEX and serum identified two monoclonal lambda LCs. Proteomics of the trypsin digested amyloid fragments in the kidney by laser microdissection and MS analysis identified a λ6 LC. The cDNA from plasma cell clone was from the IGLV- 6-57 family and it matched the amino acid sequences of the amyloid peptides. The predicted mass of the peptide product of the cDNA matched the mass of one of the two LCs identified in the UEX and serum. UEX combined with MS were able to identify 2 monoclonal lambda LCs that current clinical methods could not. It also identified the amyloidogenic LC which holds potential for response assessment in the future.
© 2017 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28295502     DOI: 10.1002/ajh.24717

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  6 in total

1.  Proteomics-inspired precision medicine for treating and understanding multiple myeloma.

Authors:  Matthew Ho; Giada Bianchi; Kenneth C Anderson
Journal:  Expert Rev Precis Med Drug Dev       Date:  2020-02-24

Review 2.  Dysproteinemias and Glomerular Disease.

Authors:  Nelson Leung; Maria E Drosou; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-07       Impact factor: 8.237

Review 3.  Immunoglobulin light chain amyloid aggregation.

Authors:  Luis M Blancas-Mejia; Pinaki Misra; Christopher J Dick; Shawna A Cooper; Keely R Redhage; Michael R Bergman; Torri L Jordan; Khansaa Maar; Marina Ramirez-Alvarado
Journal:  Chem Commun (Camb)       Date:  2018-09-20       Impact factor: 6.222

4.  Pathologic light chain amyloidosis oligomer detection in urinary extracellular vesicles as a diagnostic tool for response and progression of disease.

Authors:  Shawna A Cooper; Christopher J Dick; Pinaki Misra; Nelson Leung; Carrie A Schinstock; Marina Ramirez-Alvarado
Journal:  Front Oncol       Date:  2022-10-04       Impact factor: 5.738

Review 5.  Exosomes in Nephropathies: A Rich Source of Novel Biomarkers.

Authors:  Christos Masaoutis; Samer Al Besher; Ioannis Koutroulis; Stamatios Theocharis
Journal:  Dis Markers       Date:  2020-08-12       Impact factor: 3.434

6.  Antibody Light Chains Dictate the Specificity of Contact Hypersensitivity Effector Cell Suppression Mediated by Exosomes.

Authors:  Katarzyna Nazimek; Philip W Askenase; Krzysztof Bryniarski
Journal:  Int J Mol Sci       Date:  2018-09-07       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.